Literature DB >> 33606977

Massively parallel assessment of human variants with base editor screens.

Ruth E Hanna1, Mudra Hegde1, Christian R Fagre2, Peter C DeWeirdt1, Annabel K Sangree1, Zsofia Szegletes1, Audrey Griffith1, Marissa N Feeley1, Kendall R Sanson1, Yossef Baidi2, Luke W Koblan3, David R Liu4, James T Neal2, John G Doench5.   

Abstract

Understanding the functional consequences of single-nucleotide variants is critical to uncovering the genetic underpinnings of diseases, but technologies to characterize variants are limiting. Here, we leverage CRISPR-Cas9 cytosine base editors in pooled screens to scalably assay variants at endogenous loci in mammalian cells. We benchmark the performance of base editors in positive and negative selection screens, identifying known loss-of-function mutations in BRCA1 and BRCA2 with high precision. To demonstrate the utility of base editor screens to probe small molecule-protein interactions, we screen against BH3 mimetics and PARP inhibitors, identifying point mutations that confer drug sensitivity or resistance. We also create a library of single guide RNAs (sgRNAs) predicted to generate 52,034 ClinVar variants in 3,584 genes and conduct screens in the presence of cellular stressors, identifying loss-of-function variants in numerous DNA damage repair genes. We anticipate that this screening approach will be broadly useful to readily and scalably functionalize genetic variants.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; ClinVar; DNA damage; PARPi; apoptosis; base editing; genetic screens

Mesh:

Substances:

Year:  2021        PMID: 33606977     DOI: 10.1016/j.cell.2021.01.012

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  31 in total

Review 1.  CRISPR in cancer biology and therapy.

Authors:  Alyna Katti; Bianca J Diaz; Christina M Caragine; Neville E Sanjana; Lukas E Dow
Journal:  Nat Rev Cancer       Date:  2022-02-22       Impact factor: 60.716

Review 2.  A new era in functional genomics screens.

Authors:  Laralynne Przybyla; Luke A Gilbert
Journal:  Nat Rev Genet       Date:  2021-09-20       Impact factor: 53.242

3.  CRISPR Screens to Identify Regulators of Tumor Immunity.

Authors:  Martin W LaFleur; Arlene H Sharpe
Journal:  Annu Rev Cancer Biol       Date:  2021-12-23

4.  Base editor scanning charts the DNMT3A activity landscape.

Authors:  Nicholas Z Lue; Emma M Garcia; Kevin C Ngan; Ceejay Lee; John G Doench; Brian B Liau
Journal:  Nat Chem Biol       Date:  2022-10-20       Impact factor: 16.174

5.  Functional interrogation of DNA damage response variants with base editing screens.

Authors:  Raquel Cuella-Martin; Samuel B Hayward; Xiao Fan; Xiao Chen; Jen-Wei Huang; Angelo Taglialatela; Giuseppe Leuzzi; Junfei Zhao; Raul Rabadan; Chao Lu; Yufeng Shen; Alberto Ciccia
Journal:  Cell       Date:  2021-02-18       Impact factor: 41.582

Review 6.  CRISPR-based genome editing through the lens of DNA repair.

Authors:  Tarun S Nambiar; Lou Baudrier; Pierre Billon; Alberto Ciccia
Journal:  Mol Cell       Date:  2022-01-20       Impact factor: 17.970

7.  Restoration of DNA repair mitigates genome instability and increases productivity of Chinese hamster ovary cells.

Authors:  Philipp N Spahn; Xiaolin Zhang; Qing Hu; Huiming Lu; Nathaniel K Hamaker; Hooman Hefzi; Shangzhong Li; Chih-Chung Kuo; Yingxiang Huang; Jamie C Lee; Anthony J Davis; Peter Ly; Kelvin H Lee; Nathan E Lewis
Journal:  Biotechnol Bioeng       Date:  2022-01-05       Impact factor: 4.530

Review 8.  Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics.

Authors:  Samuel B Hayward; Alberto Ciccia
Journal:  Curr Opin Genet Dev       Date:  2021-09-25       Impact factor: 5.578

9.  CRISPR base editor screens identify variant function at scale.

Authors:  Phoebe C R Parrish; Alice H Berger
Journal:  Mol Cell       Date:  2021-02-18       Impact factor: 19.328

Review 10.  Advancing drug discovery using the power of the human genome.

Authors:  Karl Heilbron; Sahar V Mozaffari; Vladimir Vacic; Peng Yue; Wei Wang; Jingchunzi Shi; Adrian M Jubb; Steven J Pitts; Xin Wang
Journal:  J Pathol       Date:  2021-04-09       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.